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Abstract
Neglected for years, astrocytes are now recognized to 
fulfill and support many, if not all, homeostatic functions 
of the healthy central nervous system (CNS). During 
neurodegenerative diseases such as amyotrophic 
lateral sclerosis (ALS) and spinal cord injury (SCI), 
astrocytes in the vicinity of degenerating areas 
undergo both morphological and functional changes 
that might compromise their intrinsic properties. 
Evidence from human and animal studies show that 
deficient astrocyte functions or loss-of-astrocytes largely 
contribute to increased susceptibility to cell death for 
neurons, oligodendrocytes and axons during ALS and 
SCI disease progression. Despite exciting advances in 
experimental CNS repair, most of current approaches 
that are translated into clinical trials focus on the 
replacement or support of spinal neurons through 
stem cell transplantation, while none focus on the 
specific replacement of astroglial populations. Knowing 
the important functions carried out by astrocytes 
in the CNS, astrocyte replacement-based therapies 
might be a promising approach to alleviate overall 
astrocyte dysfunction, deliver neurotrophic support to 
degenerating spinal tissue and stimulate endogenous 
CNS repair abilities. Enclosed in this review, we gathered 
experimental evidence that argue in favor of astrocyte 
transplantation during ALS and SCI. Based on their 
intrinsic properties and according to the cell type 
transplanted, astrocyte precursors or stem cell-derived 
astrocytes promote axonal growth, support mechanisms 
and cells involved in myelination, are able to modulate 
the host immune response, deliver neurotrophic factors 
and provide protective molecules against oxidative or 
excitotoxic insults, amongst many possible benefits. 
Embryonic or adult stem cells can even be genetically 
engineered in order to deliver missing gene products 
and therefore maximize the chance of neuroprotection 
and functional recovery. However, before broad clinical 
translation, further preclinical data on safety, reliability 
and therapeutic efficiency should be collected. Although 
several technical challenges need to be overcome, 
we discuss the major hurdles that have already been 
met or solved by targeting the astrocyte population 
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Core tip: Amyotrophic lateral sclerosis (ALS) and 
spinal cord injury (SCI) result in incurable neurological 
dysfunction due to loss of spinal motor neurons and 
axonal degeneration, amongst other mechanisms. 
Astrocytes are increasingly recognized as being necessary 
for neuroprotection and regeneration in the central 
nervous system as they promote axonal growth and 
deliver essential neurotrophic factors under both 
physiological and pathophysiological conditions. Given 
the central role played by astrocytes, we gathered 
convincing results from ALS and SCI literature that 
argue in favor of stem cell-based astrocyte replacement 
therapies and stress the scientific community to 
investigate more deeply the molecular understanding of 
astrocyte biology.
Nicaise C, Mitrecic D, Falnikar A, Lepore AC. Transplantation 
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MULTIPLE FACETS OF ASTROCYTES IN 
THE CENTRAL NERVOUS SYSTEM
Astrocyte functions
Astrocytes are the most abundant cells in the central 
nervous system (CNS), outnumbering neuronal cells 
by several fold in some CNS regions. They have 
long been relegated to a secondary position, behind 
neurons or oligodendrocytes, as many thought that 
astrocytes were barely by-standers of the CNS. 
Accounting for a large fraction of the brain volume, 
their particular shape and tissue distribution are known 
to elaborate an extensive network of fine interconnected 
processes. Their star-shaped morphology projecting 
long branched processes provides a large coverage 
of CNS structures and the ensheathment of the brain 
or spinal cord in the pia matter. They draw the whole 
brain microanatomy by secreting astrocyte-derived 
extracellular matrix proteins (e.g., chondroitin sulfate 
proteoglycans, hyaluronan, tenascin proteins family, 
thrombospondin), thereby providing structural support 
for nervous system cells. Beside their structural role, 
astrocytes are recognized to fulfill and support many, if 
not all, functions of the healthy CNS[1]. Astrocyte end-
feet cover more than 90% of the CNS vasculature and 
come in contact with endothelial cells. Expressing key 
glucose transporter-1, astrocytes convoy glucose from 
blood vessels to nervous system cells, most of them 
being devoid of direct access to this high-end source 
of energy. Hence, astrocytes synthetize via specific 
metabolic pathways glycogen and lactate, main 
energy fuels for neurons or distant synapses. Through 
humoral factors released at the perivascular space, 
astrocytes control local cerebral blood flow and blood-
brain barrier (BBB) integrity. Transforming growth 
factor-beta, glial-derived neurotrophic factor (GDNF), 
fibroblast growth factor 2 (FGF2) and angiopoietin 1 
(binding the endothelium-specific receptor TIE2), all 
secreted at the vascular end-feet, act on endothelial 
cells in order to induce or maintain an operational 
BBB[2,3]. Astrocytes-released growth factors [e.g., brain-
derived neurotrophic factor, BDNF; ciliary neurotrophic 
factor (CNTF)] exert beneficial effects far beyond the 
perivascular space and act as neurotrophic factors on 
all CNS cells[4,5]. The perivascular end-feet of astrocytes 
show other specialized features characteristic of this 
location, including a high density of orthogonal arrays 
containing the water channel aquaporin 4 (AQP4) 
and the Kir4.1 K+ channel[6,7]. Those proteins closely 
interact with endothelial basal lamina and regulate 
ions/water fluxes through the BBB[7-10]. Astrocytes 
finely tune the dynamics of cerebral blood flow in 
order to increase the availability of oxygen and glucose 
locally to highly active brain areas; this process is 
mediated via secreted vasoactive compounds (i.e., 
endothelin-1, arachidonic acid, prostaglandins, nitric 
oxide) and intercellular Ca2+ signaling[11-13]. As a 
member of the tripartite synapse, astrocytes are 
responsible for proper neurotransmission. Astrocyte 
end-feet express Kir4.1 channel, which is responsible 
for the rapid uptake of K+ released in the interstitial 
CNS fluid and thus for spatial extracellular potassium 
siphoning needed during high-frequency firing of 
neurons[14-16]. Astrocytes also express membrane-
bound transporters and receptors involved in the 
re-uptake and the response to neurotransmitters 
(i.e., glutamate, GABA, glycine), whose synaptic 
concentrations must be tightly controlled in the 
synaptic cleft. In the case of glutamate homeostasis, 
two major CNS glutamate transporters, GLT1/EAAT2 
and GLAST/EAAT1, are expressed almost exclusively 
by astrocytes in the adult mammals. GLT1 accounts 
for upward of 90% of glutamate uptake in most CNS 
regions[17]. By regulating extracellular glutamate 
homeostasis, GLT1 assures proper synaptic function 
and prevents excitotoxic insult to susceptible neurons, 
axons and oligodendrocytes. In addition, astrocytes 
form a gap junction-coupled network of very narrow 
overlapping domains throughout the CNS[18,19]. Each 
domain covers a CNS area encompassing from 
20000 neuronal synapses in rodents up to 2000000 
in humans and connects neighboring astrocytes by 
Nicaise C et al . Astrocyte therapy for ALS and SCI
381 March 26, 2015|Volume 7|Issue 2|WJSC|www.wjgnet.com
junctional complexes made of connexin (Cx) family 
proteins. On a functional point-of-view, the astrocyte 
syncytium supports ATP-mediated long-distance 
propagation of Ca2+ waves[20,21], which is involved in 
the control of local cerebral blood flow and the fine 
tuning of electrical neuronal activity[22]. Cx channels 
allow the intercellular passage of monovalent ions 
(Na+, K+) or small molecules up to 1.5 kDa (e.g., ATP, 
glutamate, d-serine), contributing to signaling, metabolic 
cooperation and ionic spatial buffering[23,24]. Astrocytes 
express Cx26, Cx30 and Cx43 that interact with 
homologous connexins in astrocyte-to-astrocyte (A/A) 
gap junctions and that can also bind in a heterologous 
fashion Cx29, Cx32 and Cx47 on oligodendrocytes 
partners[24-26]. In mammals at least, the presence of 
theses 6 connexins suggests a high level of complexity 
in coupling partners within the glial cell populations and 
reveals close cellular interactions between astrocytes 
and oligodendrocytes. Astrocyte-oligodendrocyte 
(A/O) coupling via connexins is necessary to sustain 
myelin formation and maintenance throughout life. In 
humans, mutations in Cx29, Cx32 and Cx47 genes 
lead to myelin formation abnormalities and are linked 
to Charcot-Marie-Tooth disease and several forms 
of leukodystrophies[27]. Beyond mutations targeting 
oligodendroglial connexins, the effect of loss-of-function 
of astrocyte connexins has been experimentally 
investigated using knockout mice. Double Cx30-/- 
and Cx43-/- knockout mice showed white matter 
pathology comprising vacuolated oligodendrocytes and 
intramyelinic edema[28]. Histopathological changes were 
accompanied by significant sensorimotor and cognitive 
deficits. Similar findings were shown when double-
deleting Cx43 and Cx32 in mice[29]. All of these findings 
suggest an essential role of A/A and A/O coupling in 
maintaining overall CNS functions[30] and pave the 
way for developing integrated therapies targeting the 
astrocyte syncytium and its dysfunction(s) during 
neurodegenerative conditions.
Wealth through diversity
A rapid look at the morphology of white matter 
astrocytes compared to gray matter astrocytes reveals 
the complexity and heterogeneity of this class of 
cells. Their different morphologies are most likely to 
be related with their wide range of functions, their 
neuroanatomical sites and the stem cells from which 
they derive (reviewed by[31]). During development, 
astrocytes mainly arise from radial glial cells located in 
the brain and spinal cord. During adulthood, astrocytes 
are still generated from differentiating progenitors in 
stem cell niches[32] or from dividing mature astrocytes 
in specific brain regions[33]. Historically, two classes 
of astrocytes were described: “type Ⅰ” fibrous 
astrocytes mostly found in white matter tracts and 
“type Ⅱ” protoplasmic astrocytes found in the grey 
matter[34,35]. Nowadays, the scientific community 
agrees that astrocyte complexity, in particular within 
the protoplasmic subfamily, has increased along 
with phylogenic evolution. As far as we know, this 
complexity culminates in the human CNS. Compared 
to rodents[19], human astrocytes have a greater size, a 
more complex morphology, a large pleiomorphism[36] 
and are able to propagate calcium waves five times 
more rapidly[31,37,38]. Although mice represent a useful 
tool to study astrocytes and their in vivo functions 
through genetic manipulation, one limitation of rodent-
to-human extrapolations is the wider diversity of human 
counterparts. For instance, primate brain contains 
two types of astrocytes not found in rodent brain: 
interlaminar and varicose astrocytes, whose functions 
are as of yet undetermined but seem to be related to 
the higher complexity of neuronal layers inside the 
human cortex[37]. Despite this heterogeneity, astrocytes 
share similarities such as the expression of several 
common proteins. Intermediate filament proteins are 
very abundant in the cytoplasmic compartment among 
all astrocytes types: glial fibrillary acidic protein (GFAP), 
vimentin, desmin and synemin. Recently, the cell 
surface marker CD44, the receptor of extracellular 
matrix hyaluronan, has been described to distinguish, 
more accurately than GFAP, protoplasmic astrocytes 
from fibrous-like astrocytes[36]. Resting astrocytes 
also display specific immunoreactivity for aldehyde 
dehydrogenase 1 family member L1, AQP4, S100, GLT1, 
GLAST and glutamine synthetase. Under pathological 
conditions affecting CNS [e.g., Alzheimer’s disease, 
multiple sclerosis, stroke, amyotrophic laterals sclerosis 
(ALS), spinal cord injury (SCI)], astrocytes can switch 
to an activated phenotype. Activated astrocytes, which 
can in some case include a population of proliferating 
astrocytes, are commonly observed around focal 
CNS lesions, in areas of neuronal loss/damage, in 
demyelinating areas, during neuroinflammation 
or during CNS repair. Astrocyte hypertrophy and 
upregulation of GFAP, vimentin, nestin or S100 are 
hallmarks of activated astrocytes. For instance, new 
protein markers may also be expressed. Expression 
of S100A6, a calcium binding protein, is drastically 
increased in astrocytes from ALS spinal cord[39,40], 
after traumatic CNS injury[41] or in Alzheimer brain 
tissue[42]. Given that ALS and SCI affect either diffuse 
or discrete areas, respectively within the CNS (i.e., in 
ALS from motor cortex to bulbar respiratory nuclei to 
the lumbar spinal motor neurons; in SCI, both gray 
and white matter astrocytes are lost over a distance 
of several millimeters), therapeutically-targeting 
astrocytes would undoubtedly take into account their 
diversity of shape and function, with respect to their 
location. Our knowledge about astrocyte heterogeneity 
now allows for generating in vitro subpopulations of 
stem cell-derived astrocytes endowed with specific 
fates or defined functional abilities. These cells, 
isolated and expanded in vitro, can be further used 
in transplantation paradigms aiming at providing 
neuroprotection or replacing astrocyte-deficient 
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spherical aggregates called “neurospheres” or adherent 
layers of cells when supplemented with epidermal 
growth factor and fibroblast growth factor 2. Culture 
conditions involving growth factor withdrawal and 
serum exposure elicit a differentiation program into 
either neurons, oligodendrocytes or GFAP+ astrocytes, 
with various yields[52-54]. Transplantation of NSCs into 
the CNS results in the generation of multiple cell 
types, including astrocytes[53] and oligodendrocytes[55]. 
Another source of astrocytes in the adult CNS is radial 
glial cells[56,57]. Several lines of evidence support the 
existence of a small pool of such cells expressing 
classic radial glial markers (i.e., NG2, RC1, 3CB2, brain 
lipid-binding protein)[58] and located in limited regions 
of ongoing neurogenesis in the adult CNS[59-61].
Embryonic or Induced-pluripotent stem cells
Embryonic stem cells (ESCs) and induced-pluripotent 
stem cells (iPSCs) represent an ideal pluripotent 
source for deriving human astrocytes. Even though 
early reports demonstrated differentiation of astrocytes 
from human iPSCs or ESCs, there was a great diversity 
in terms of reported methods and the total yields of 
neural cells were not high. Furthermore, astrocytes 
generated by these protocols were not defined in 
terms of their subtype identity. On the other hand, 
specific protocols to generate astrocytes with regional 
or subtype identity were not reported[62-68]. This gap 
was fulfilled by a recently reported protocol, which 
allows directed differentiation of astrocytes via a prior 
differentiation of human stem cell derived neuro-
epithelial cells into glial progenitor cells by repression 
of neurogenesis. Astrocytes generated by this protocol 
were characterized by specific gene expression 
profiles, neurotransmitter and ionic uptake, support 
of neuronal maturation, and importantly expression 
of specific sets of homeodomain transcription factors 
that specify functional identity[69]. On the basis of 
this, another protocol was recently reported for an 
efficient generation of immature astrocytes from 
human pluripotent stem cells (hPSCs)[70]. The protocol 
consists of three steps. In the first stage, hPSCs 
were differentiated into neuroepithelial cells either 
by co-culturing with mouse embryonic fibroblasts 
or by differentiation in feeder free conditions. These 
appeared in the form of columnar epithelia that 
organized into neural tube-like rosettes at about day 
10-15 of differentiation. Addition of morphogens 
at days 8 to 15 allows differentiation of specific 
astrocyte subtypes. In the second stage, floating neural 
progenitor aggregates were expanded with epidermal 
growth factor, FGF2 and mitogenic factors. Neuronal 
differentiation was repressed and potential for gliogenic 
progenitor was enhanced by weekly mechanical 
trituration. By around 90 d, most of the progenitors 
expressed markers for astrocyte progenitors or 
astrocytes such as CD44 and S100. Thus at this stage, 
they are referred to as “astrospheres”. In the third and 
functions observed during neurodegenerative and 
traumatic diseases of the spinal cord such as ALS or 
SCI. 
SOURCES OF STEM CELL-DERIVED 
ASTROCYTES 
Glial-restricted precursor cells 
Use of lineage-restricted progenitors as a source 
for deriving astrocytes has gained wide popularity 
in recent years due to their ability to generate 
specific glial types following transplantation. Glial-
restricted progenitors are present in the embryonic 
spinal cord and through their ability to self-renew 
and differentiate give rise to oligodendrocytes and 
astrocyte populations. The first type of glial restricted 
progenitor that was originally characterized was the 
A2B5+ O-2A progenitor cell. This was isolated from 
optic nerve of embryonic and post-natal rats and 
through in vitro differentiation was shown to be able 
to differentiate into oligodendrocytes and a particular 
type of astrocyte called the type-2 astrocyte[43-45]. 
More recently, a different type of progenitor cell 
was characterized that is able to differentiate into 
oligodendrocytes and two different populations of 
astrocytes. This cell type was isolated from E13.5 
rat spinal cord and is also positive for the A2B5 
antigen.  In vitro conditions that supported their above 
mentioned differentiation included culture medium 
supplemented with fetal calf serum or platelet-derived 
growth factor (PDGF) and T3 thyroid hormone. Clonal 
analysis confirmed that these individual GRPs are 
tripotent. Furthermore, these cells are capable of 
extensive self-renewal in the presence of PDGF and 
FGF2. These GRPs differed from the original A2B5+ 
O-2A progenitor cell in several aspects such as 
absence of mitogen requirements, responsiveness to 
PDGF and morphologies[46]. 
Neural stem cells or radial glia
Using cell genesis and fate specifying processes, 
neural tube-derived neural stem cells give rise to 1011 
neurons and at least 1012 glial cells of many different 
phenotypes in the adult brain[47-49]. Neural stem cells 
(NSCs) are an attractive source for generating astroglial 
cells through their multipotency and high potential 
of self-renewal. NSCs represent an endogenous 
population existing during brain development and to 
a lesser extent in adult brain niches. In adult CNS, 
they are found around the sub-ventricular zone, the 
sub-granular layer of the hippocampus and spinal 
ependymal canal. Their phenotype is characterized by 
an astrocyte-like morphology and GFAP expression[50,51] 
together with other markers of an undifferentiated 
state (e.g., nestin, SOX2). The most common sources 
for NSC isolation include embryonic brain cortex and 
adult sub-ventricular zones. One of the basic features 
of NSCs is that they can easily divide in vitro either as 
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final stage, astroglial progenitors were differentiated 
into functional astrocytes by removal of mitogens. 
Addition of CNTF for 6 d stimulated gliogenic gene 
expression. If neuroepithelial cells were patterned in 
stage 1, terminally differentiated astrocytes expressed 
specific markers such as Hoxb4 for posterior identity 
or Nkx2.1 for ventral identity. 
In vivo or in vitro transdifferentiation 
Some cases of in vivo transdifferentiation into 
astrocytes have been described in the literature 
following transplantation of bone marrow-derived 
stem cells or mesenchymal stem cells into rodent 
CNS. It is not yet clear whether transdifferentiation 
normally occurs in healthy CNS and, if so, whether 
it requires a de-differentiation step. Several criteria 
must be filled to truly establish transdifferentiation into 
astrocytes: original cells must lose their committed-
lineage differentiation markers; they have to adopt 
a astrocyte-like morphology and express astrocyte 
markers (e.g., GFAP, S100). Several reports showed 
that GFP reporter-expressing bone marrow stem 
cells transplanted into adult rodent CNS gave rise to 
GFP+ GFAP+ astrocytes[71-73]. Similarly, mesenchymal 
stem cells (MSCs) isolated from bone marrow, when 
grafted into neonatal mouse brain, have been shown 
to migrate extensively and differentiate into olfactory 
bulb granule cells and astrocytes[74]. In an original 
experimental approach, Boucherie and colleagues 
intrathecally grafted MSCs in ALS-affected rodent 
spinal cord and observed that MSCs were able to 
extensively migrate while differentiating mostly into 
astrocytes at the sites of neurodegeneration[75]. In 
recent years, in vitro transdifferentiation, starting from 
single skin fibroblasts, has also made possible the 
modeling of CNS diseases in a dish, bypassing invasive 
neurosurgical procedures to get human diseased 
tissue. Recent cell reprogramming protocols describe 
the direct conversion of human fibroblasts to “induced” 
neural stem cells, able to further differentiate into 
the three CNS lineages (neurons, astrocytes and 
oligodendrocytes) following appropriate culture 
conditions. Artificial and temporal expression of specific 
transcription factors such as Oct-3/4, Sox2, Klf4, 
Brn4 and c-myc seems to govern the cell conversion 
towards a neural fate[76-78]. Molecular pathways and 
key transcription factors making transdifferentiation 
possible are currently under investigation for different 
cell types[79].
RATIONALE FOR ASTROCYTE 
REPLACEMENT IN ALS AND SCI
What is amyotrophic lateral sclerosis? 
Amyotrophic lateral sclerosis (ALS) is a common 
adult-onset neurodegenerative disease of the motor 
system, with a prevalence of 2-5/100000 people. 
It is characterized by a rapidly progressing neurode-
generation selectively affecting cortical, brainstem and 
spinal motor neurons. ALS remains an incurable disease, 
leading to fatal respiratory failure usually within 5 years 
following diagnosis[80]. Pathophysiology of ALS is poorly 
understood and likely multifactorial. Proposed starting 
points for this complex disease targeting the motor 
neuron population include mitochondrial dysfunction, 
intracellular protein aggregation, disturbances of 
RNA metabolism, extracellular toxic environment, 
impairment at the level of axonal transport and at the 
neuromuscular synapse (reviewed by[81]), together with 
extrinsic events: blood-brain barrier breakdown, glial 
cell reaction/dysfunction and neuroinflammation[82-88]. 
It is known that dying motor neurons influence 
surrounding cells, of which astrocytes are most commonly 
investigated. Astrocytes shift from an anti-inflammatory 
and neuroprotective role to one that is pro-inflammatory 
and neurotoxic, thus adding to complexity of this fatal 
cascade[80]. In 5%-10% of patients, ALS is inherited 
(familial ALS). In those cases, every fifth patient carries 
a detected mutation in superoxide dismutase 1 (SOD1), 
which is at present the most reliable and most widely 
used genetic animal model for ALS[89]. Among others, 
the most commonly described mutations include genes 
encoding the DNA/RNA-binding proteins FUS, TDP43[90], 
the ubiquitin-like protein Ubiquilin 2[91] and optineurin[92]. 
On the other hand, an intronic hexanucleotide repeat in 
the C9ORF72 gene was discovered in both familial and 
sporadic cases of ALS[93]. 
What are spinal cord injuries? 
SCI are devastating and diverse set of conditions 
that result from damage to spinal cord grey matter 
and white matter, as well as corresponding spinal 
nerves. The National Statistics for SCI estimates 
approximately 12000 new cases each year in the 
United States alone, most of which result from 
preventable causes (e.g., motor vehicle accidents, 
falls, sports or violence). Some common outcomes 
of SCI include dysfunctions in the musculoskeletal, 
respiratory, uro-genital and gastrointestinal systems. 
The diversity of this condition results from differences 
in the location, type and severity of trauma, as well 
as on the consequent types and degree of functional 
impairment. Despite this diversity, all forms of SCI are 
linked to specific phenotypic changes in populations 
of spinal cord astrocytes. Some examples of these 
changes are: (1) acquisition of specific protective 
functions such as glial scar formation to constrain the 
secondary expansion of the lesion; (2) loss of certain 
crucial homeostatic functions such as the astrocyte 
glutamate transporter system that are key to normal 
CNS physiology; and (3) gain of toxic functions such 
as the generation of pro-inflammatory signaling 
molecules that contribute to degeneration, neuronal 
hyperexcitability and other detrimental effects. The 
response of astrocytes is a gradated response such 
that there is diversity in these changes that vary with 
the type and severity of trauma and with proximity 
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to the lesion. Furthermore, even within a population 
of astrocytes within the spinal cord, the response of 
individual astrocytes to the same injury can vary, 
likely reflecting the normal heterogeneity amongst 
astrocytes that is now becoming increasingly 
appreciated. 
Defective astrocyte glutamate handling: one rationale 
among others 
ALS and SCI are both spinal cord disorders involving all 
CNS cells: neurons, oligodendrocytes, microglial cells, 
endothelial cells and astrocytes. In both cases, there 
is significant motor, as well as sensory, dysfunction, 
although sensory involvement is still a matter of debate 
in ALS. To some extent, they share histopathological 
features in the spinal cord tissue: death of spinal 
motor neurons, axonal damage in white matter tracts, 
anterograde axonal degeneration, BBB dysfunction, 
impaired astrocyte function and neuroinflammation. In 
the case where neurodegeneration reaches the cervical 
level of the spinal cord, the loss of phrenic motor 
neurons that control contraction of the diaphragm leads 
to severe respiratory deficits and represents a life-
threatening condition. ALS, historically characterized 
by the loss of upper and lower motor neurons, is 
more and more recognized as endowed with a non-
cell-autonomous component, in which microglia and 
astrocytes act as significant contributors to overall 
spinal cord dysfunction. It has been shown that 
microglia carrying ALS-linked mutant SOD1 drive ALS 
disease progression by fostering neuroinflammation 
and a toxic environment for spinal motor neurons[81,94]. 
With respect to astrocytes in ALS, independent groups 
demonstrated that astrocytes bearing mutant SOD1 
are key determinants of disease progression[95-97]. 
In the absence of any pathology, normal astrocytes 
uptake glutamate, released at the synaptic cleft, 
through their glutamate transporters (GLT1/EAAT2 
and GLAST/EAAT1). Furthermore, normal astrocytes 
protect motor neurons from glutamate excitotoxicity 
by stimulating the neuronal expression of AMPA-GluR2, 
which is less permeable to calcium making motor 
neurons less sensitive to excitotoxicity[98]. During ALS 
disease course, it is known from human and animal 
model samples that astrocyte-based glutamate uptake 
is compromised due to an early loss of astrocyte GLT1. 
Drastic GLT1 downregulation is most likely to be linked 
with deleterious extrasynaptic glutamate accumulation, 
which gave rise to the theory of glutamate-induced 
excitotoxic motor neuron death and to the unique FDA-
approved drug that slows ALS: Riluzole, based on its 
anti-glutamatergic action. 
Following SCI, the entire architecture of the spinal 
cord is disrupted at the lesion site; the trauma produces 
both immediate and delayed cell death affecting all 
nervous system populations: neurons, astrocytes 
and oligodendrocytes. Shortly after injury, it has been 
demonstrated that glutamate starts to accumulate in 
the extracellular space[99], and can persist for over a 
week, depending on injury severity[100]. Overload of 
CNS extracellular glutamate may cause excitotoxic 
damage to neurons, axons and oligodendrocytes via 
overactivation of both AMPA and NMDA receptors[101,102]. 
Failure of long-term extrasynaptic glutamate clearance is 
suspected to be one major cause of secondary cell loss 
following SCI. Noteworthy, we and others demonstrated 
that astrocyte GLT1 was chronically lost at the injury 
epicenter following SCI but also downregulated in 
spinal cord regions distant from the lesion core[103-106]. 
Furthermore, experimental data showed that the newly-
generated astrocytes arising during the SCI repair 
phase lacked GLT1 expression, possibly compromising 
long-term astrocyte glutamate homeostasis[107]. Other 
consequences of astrocyte dysfunction or loss should 
be considered in ALS and SCI: shortage of neurotrophic 
factors important for neuronal survival, overwhelming 
of anti-oxidative defenses, lack of support to maintain 
endothelial BBB integrity, impaired water, ionic and 
metabolic transport, release of harmful proinflammatory 
cytokines and synthesis of glial scar-related ECM 
proteins that block axonal regrowth[1]. Regardless of 
whether astrocyte dysfunction is a cause of disease 
or a consequence of neuronal loss, altered physiology 
of pathologic astrocytes likely results in further 
susceptibility to CNS tissue loss, justifying the rationale 
for transplantation-based astrocyte replacement[108]. 
Numerous studies indicate that transplantation of stem 
cell-derived astrocytes has exhibited beneficial effects 
on histological/functional outcomes in ALS and SCI 
animal models. In this review, we summarize the data 
from recent literature regarding transplantation of stem 
cell-derived astrocytes targeting the replacement of 
deficient or lost astrocytes during ALS and SCI.
METHODOLOGICAL CONSIDERATIONS
Feasibility of astrocyte transplantation in healthy spinal 
cord
Pilot studies were done on spinal GRPs isolated and 
characterized from the human aborted embryos[46,109,110]. 
Upon transplantation into neonatal and adult rodent 
brain, human GRPs survived, migrated and diffe-
rentiated into (im)mature oligodendrocytes and into 
GFAP-expressing astrocytes[111]. These results were 
later confirmed by another group who analyzed the 
fate of GRPs harvested from alkaline phosphatase-
expressing transgenic rats injected into intact and 
injured spinal cord. In the first set of experiments, 
GRPs survived at least 6 wk[112] and in the second 
experiment up to 15 mo post-transplantation[113], 
demonstrating their long-term integration. Cells 
showed morphological maturation and differentiated 
along astrocyte and oligodendrocyte lineages and not 
into neuronal lineages. Interestingly, cells grafted into 
the intact spinal cord showed a particular tropism for 
white matter tracts and robust migration capacities 
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since they were found more than 15 mm away from 
the injection sites[112,113]. Transplantation of GRP-
derived astrocytes seems to be a safe procedure, 
at least experimentally, since no tumor formation 
or pronounced immune response were observed at 
the graft sites. Isolated human GRPs express in vitro 
functional glutamate transporters EAAT1, EAAT3 and 
EAAT4 but not GLT1/EAAT2[114]. According to the nature 
of in vitro pre-differentiation signals, GRPs do not 
give rise to homogenous astrocyte populations upon 
transplantation[115,116]. Following bone morphogenic 
protein 4 (BMP4) driven differentiation, GRPs start to 
express EAAT2/GLT1 together with AQP4, AKAP12, 
Cx43 as markers of mature astrocytes[116]. On the 
contrary, in vitro GRP exposure to CNTF give rise to 
mature astrocytes expressing FGF receptor-3 and 
several axon growth inhibitory proteoglycans, such as 
neurocan, brevican and phosphacan, suggestive of a 
phenotype of reactive astrocytes.
Routes of administration 
Considering the route of administration for a stem 
cell therapy product is a significant factor when 
targeting the CNS and the spinal cord in particular. 
Stem cell transplantation into the spinal cord 
was successfully reported, in terms of homing 
and long-term engraftment, using different cell 
populations and different route of administration. 
Intraparenchymal injections of MSCs and NSCs into 
the thoracolumbar region[117-123] and of GRPs into the 
cervical region[104,124] have been successfully reported 
in animal models of ALS. Although direct targeting 
of the spinal cord is technically challenging and an 
invasive application, this route promises to be the 
most versatile and accurate method of targeted CNS 
therapeutic delivery, and therefore has been chosen 
for clinical translation of stem cell-based therapies 
in ALS patients. As both ALS and SCI affect long 
segments of spinal cord (several millimeters long and 
sometimes independent regions within the cord), a 
need for multiple injections adds to the complexity 
of the procedure. Aware of this issue, neurosurgeons 
are developing new surgical techniques or tools (e.g., 
radially-branched cannulae) able to deliver therapeutic 
agents to large CNS areas in a single shot[125]. Other 
attempts to find the optimal delivery route used 
intranasal[126], intrathecal[127-129], intraperitoneal[130], 
intramuscular[131], intravenous[132-135] and intra-bone 
marrow cell[136] transplantation. Major shortcomings 
are poor CNS homing of the therapeutic product 
compared to the initial dose given (dilution of cells 
in unwanted organs/sites) and adverse effects such 
as blockade of intravenously-injected stem cells 
in lung capillaries or spleen (reviewed by[137]). In 
many cases, researchers reported beneficial effects 
of peripherally-delivered stem cells associated with 
improved histological and functional outcomes in 
ALS animal models. While various routes of stem cell 
delivery have been investigated in ALS therapy (Table 
1), experimental SCI pathology was mainly targeted 
by focal stem cell injections in and around the lesion 
core, regardless of the spinal level affected (Table 2). 
Although the most efficient delivery method is still a 
matter of debate, the dose of transplanted cells, the 
timing, the location, the type of cells for particular 
needs, and their migratory abilities are additional 
parameters to take into account in designing CNS 
stem cell-based therapies. Numerous preclinical 
studies using animal transplantation paradigms will 
still be required to assess biodistribution, viability, 
integration into host tissue, differentiation into 
functional cells, lack of tumorigenicity and safety of 
delivery before broad clinical application[138-140].
LESSONS FROM TRANSPLANTATION 
PARADIGMS IN ALS MODELS 
Taking into account that neurons represent only a 
portion of the various nervous system cell types, it is 
not surprising that during onset and especially during 
progression of disease non-neuronal cells contribute 
significantly to neuronal dysfunction and death. For 
example, it has been shown that wild-type motor 
neurons in close proximity to mutant SOD1-containing 
non-neuronal cells became affected by pathological 
chain reactions specific for ALS and eventually die 
with many features of this disease[141]. In the same 
way, wild type non-neuronal cells extend survival of 
SOD1 mutant motor neurons[142]. It has been clearly 
shown that reduction of mutant SOD1 selectively 
in astrocytes results in a prolongation of disease 
duration, but has no effects on disease onset. At least 
a part of this process is modulated by dysfunction and 
decrease in levels of the primary astrocyte glutamate 
transporter, GLT1, in areas of motor neuron loss[143]. 
Taken together, these results suggest a particular role 
for astrocytes in later progression of disease[81,97]. 
Main studies that have assessed replacement of 
astrocytes based on transplantation in ALS animal 
models have been gathered in Table 1.
Transplantation of wild-type astrocytes or their 
precursors into CNS tissue affected by ALS represents 
a promising experimental approach. With the aim 
to rescue motor neurons responsible for breathing, 
which is the primary cause of death in human ALS, 
GRPs were transplanted into the cervical spinal cord 
of the SOD1G93A rat model. GRPs survived in diseased 
tissue (32.2% ± 4.6% of transplanted cells survived 
at least 80 d post-transplantation), differentiated 
efficiently into astrocytes, and reduced microgliosis 
in the cervical spinal cord. Most notably, GRPs 
extended survival and disease duration, attenuated 
motor neuron loss, and slowed declines in forelimb 
motor and respiratory function. Since GRPs that 
did not express the glutamate transporter GLT1 did 
not have similar effects on behavioral measures or 
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animal survival, this highly suggested that glutamate-
relevant pathways contribute to the cascade of events 
leading to cell death in this model and that the focal 
beneficial effects of GRP transplantation could be 
explained, at least in part, by increases in glutamate 
transporter expression[104].
With the aim to translate astrocyte-based trans-
plantation towards treatment of patients, human 
GRPs have been transplanted into SOD1G9A3 mice. At 
disease end-stage, 10% of initial hGRP transplants 
survived and distributed throughout of the cervical 
spinal cord and up to 80% of all human derived cells 
co-expressed the astrocyte marker GFAP. Unlike 
the results obtained with rodent-derived GRPs, this 
xenograft transplantation paradigm using human GRPs 
did not provide a phenotypic preservation of motor 
function[124]. 
In another study, Boucherie and colleagues tested 
a different approach: they injected MSCs into the 
cerebrospinal fluid of symptomatic SOD1G93A rats. They 
successfully penetrated the CNS parenchyma and 
accumulated at sites of motor neuron degeneration. 
They differentiated into astrocytes and, most notably, 
decreased motor neuron loss in the lumbar spinal cord, 
preserving hindlimb motor function and extending 
the survival of SOD1G93A rats. This neuroprotection 
correlated with decreased inflammation, as shown by 
a decrease in the proliferation of microglial cells and 
reduced expression of inflammatory-related genes, 
COX-2 and NOX-2[75]. Recent publications confirmed 
that transplantation of stem cells indeed reduces 
neuroinflammation and suggests that alleviating 
astrocytosis or microgliosis is an important parameter 
leading to both histological and functional improvement 
in ALS animal models[144,145].
Another approach was tested by Mitrecić et al[135]. 
They transplanted NSCs into the rat model of ALS 
using the intravascular route. It was clearly shown 
that in animals affected by disease cells did cross the 
blood-brain barrier and accumulated in the regions 
affected by disease (motor cortex, ventral horns of 
the spinal cord) more than in healthy non-diseased 
animals. In the diseased CNS tissue, although only 
6% of the initial stem cell dose was found at 7 d 
post-infusion, the transplanted cells differentiated 
into neurons and astrocytes[135]. Transplantation of 
genetically-engineered cells is another strategy to 
provide additional support or growth factors to ALS-
affected cells and could also unexpectedly influence 
(stem) cell differentiation. This is what happened in a 
study from Rizvanov et al[146] who showed that wild-
type human umbilical cord blood cells differentiated into 
endothelial and microglial lineages after transplantation 
into SOD1G93A mice, while the same cells genetically 
modified to overexpress vascular endothelial growth 
factor (VEGF) and FGF2 exhibited preferentially 
an astrocytic differentiation[146]. In the same vein, 
human neural precursors were also genetically 
engineered to express insulin-like growth factor-1, 
neurotrophin-3, BDNF, VEGF or GDNF. These cells 
were then transplanted into the spinal cord or brain of 
SOD1G93A mice where they migrated and differentiated 
into neurons, oligodendrocytes or GLT1-expressing 
astrocytes. Unfortunately, although cells of interest 
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Table 1  Transplantation-based astrocyte replacement in amyotrophic lateral sclerosis animal models
Animal Type of cells Delivery Effect on disease Main outcomes Ref.
SOD1G93A ALS rats 
(80 d-old)
GRPs from rat E13.5 spinal cord, 
wild-type and overexpressing 
GLT1
Injections into C4-C6 
cervical spinal cord, 6 sites, 
bilateral 1.5 × 105 cells/site
Delayed decline in 
motor function and 
survival extension
Differentiation into functional 
astrocytes. Prevented motor neurons 
loss independently from growth factors 
secretion, sustained GLT1 levels, 
alleviated microgliosis
[104]
SOD1G93A ALS mice 
(75 d-old)
Human neural precursors (hNPs) 
overexpressing BDNF, IGF-1, 
VEGF, NT-3, or GDNF
Injection in cisterna magna 
and cerebral ventricles
No effect on motor 
function or animal 
survival
Differentiation in GFAP+ GLT1-
expressing and growth factors-secreting 
astrocytes. Prevented motor neurons 
loss
[147]
SOD1G93A ALS rats 
(90 d-old)
Rat adult MSCs Intrathecal delivery in 
lumbar cisterna magna, 1.95 
× 106 cells
Preserved motor 
function and 
survival extension
Differentiation into astroglial cells. 
Decreased neuroinflammation
[75]
SOD1G93A ALS mice 
(24-26 wk-old)
Human umbilical cord blood cells 
overexpressing VEGF and FGF2
Intravenous delivery, 1 × 
106 cells
Not investigated Differentiation in S100+ astrocytes [146]
SOD1G93A ALS rats 
(14-26 wk-old)
NSCs from rat E16 brain cortex Intravenous delivery, 1 × 
107 cells
Not investigated Preferential homing to late 
symptomatic ALS brain and spinal 
cord. Differentiation into neurons and 
astrocytes
[135]
SOD1G93A ALS mice 
(50-60 d-old)
hGRPs from fetal cadaver brain 
tissue (week 17-24 of  gestational)
Injections into C4-C5 
cervical spinal cord, 4 sites, 
bilateral 1.2 × 105 cells/site
No effect on 
histological or 
functional outcomes
Poor cell survival [124]
ALS: Amyotrophic lateral sclerosis; BDNF: Brain-derived neurotrophic factor; C: Cervical; E: Embryonic; FGF2: Fibroblast growth factor 2; GDNF: Glial cell-
derived neurotrophic factor; GFAP: Glial fibrillary acidic protein; GLT1: Glutamate transporter 1; GRP: Glial-restricted precursor; IGF-1: Insulin-like growth 
factor 1; MSC: Mesenchymal stem cell; NP: Neural precursor; NSC: Neural stem cell; NT-3: Neutrophin-3; SOD1: Superoxide dismutase 1; VEGF: Vascular 
endothelial growth factor.
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were generated and produced substantial amount 
of growth factors, they were unable to modify ALS 
disease onset or progression[147].
In the last few years, we have been witnessing 
translation of the basic research into clinical trials for 
ALS. Maybe too prematurely, clinical trials have been 
launched around the world, without consensus on 
the cell types used, the delivery methods, or targeted 
outcome measurements. The majority of the these 
studies have focused on safety measurements, and 
all of them have reported transplantation of stem 
cells as a safe procedure (reviewed by[148]). As we 
are approaching the stage when some of these trials 
are moving from phase 1/2 to phase 2/3, the field is 
eagerly awaiting detailed reports of the clinical benefits 
of these cellular interventions. Currently, there are 
approximately 15 ongoing clinical trials in the EU and 
United States. Most of them are focused on intraspinal 
delivery of fetal/mesenchymal/neural stem cells (United 
States, Italy, Spain) and some used intrathecal delivery 
of autologous bone marrow-derived cells; so far, none 
of them is specifically addressing the replacement of 
ALS-affected astrocytes. 
LESSONS FROM TRANSPLANTATION 
PARADIGMS IN SCI MODELS 
Some of the major experimental studies addressing 
the replacement of astrocytes based on transplantation 
paradigm in SCI animal models are summarized in Table 2. 
Historical studies conducted in the laboratories of George 
Smith and Jerry Silver tested the therapeutic potential 
of rodent neonatal astrocytes by transplantation 
following CNS insults. In this paradigm, cerebral 
midline was lesioned causing severing of callosal 
axons. A nitrocellulose bridge was introduced at the 
site of injury. When conducted at postnatal day 8 or 
younger ages, no necrosis was observed within 24 h. 
Furthermore, glial cells migrated and integrated into 
the graft, which provided a substrate for axon growth. 
However, when conducted later, there was extensive 
tissue degeneration and the implant was covered 
with a scar like mixture of fibroblasts and astrocytes. 
This glial scar failed to promote axon regeneration. 
Interestingly, when this paradigm was modified such 
that glial cells from younger pups were grafted into 
lesions of the older pups, they retained their ability to 
promote axon outgrowth. These pioneering studies 
demonstrated an age dependent decrease in the ability 
of endogenous and transplanted astrocytes to promote 
axon regeneration[149]. 
Successive in vitro studies conducted by these 
researchers confirmed age dependent changes in 
intrinsic properties and molecular basis for supporting 
axon growth in astrocytes. The rate and extent of chick, 
as well as rodent, axon outgrowth was consistently 
greater over the surface of immature compared to 
mature astrocytes. In terms of molecular properties, 
NCAM and G4/L1 antibodies reduced the rate of 
outgrowth over immature but not mature astrocytes, 
whereas integrin B1 receptor antibody reduced 
outgrowth on immature, and to a lesser extent, over 
mature astrocytes[150]. 
Furthermore, there are differences in the motile 
properties of the two cell populations such that following 
transplantation into adult brain immature astrocytes 
demonstrate extensive migration and interaction 
with host blood vessels, unlike mature astrocytes. 
This ability may be linked to their potential to limit 
glial scar formation and support axon outgrowth[151]. 
Transplantation of neonatal astrocytes at the site of 
thoracic SCI resulted in outgrowth of axons along the 
transplants, as well as some motor recovery[152]. 
Even though these early studies produced promising 
results, because of the difficulty in harvesting these 
beneficial immature astrocytes from human tissues, 
further studies explored more practically relevant cell 
types such as multipotent NSCs as a viable source 
to generate transplantable astrocyte populations. In 
studies conducted by the Whittemore lab, NSCs isolated 
from E14 rat cortex were transplanted into intact and 
injured spinal cord, without prior differentiation. In 
the intact spinal cord, over a 2-mo period, a 50% of 
multipotent stem cells differentiated into GFAP positive 
astrocytes and a small percentage differentiated into 
oligodendrocytes and neurons. Following injury to the 
spinal cord,  astrocyte differentiation dropped to 35% 
and neuronal differentiation was not observed at all[153], 
demonstrating an effect of the micro-environment on 
the differentiation pattern of the transplanted stem 
cells. To overcome this, in a separate study, NSCs were 
transfected with Ngn-2, followed by transplantation 
into injured spinal cord. This resulted in a significant 
reduction in astrocyte differentiation and an increase 
in differentiation into oligodendrocytes and neurons. 
Furthermore, Ngn-2-NSC treated rats showed improved 
motor function. These studies also showed that 
transplantation of control NSCs enhanced neuropathic 
pain associated with SCI, whereas this unexpected side 
effect was not observed in Ngn-2-NSC transplanted 
rats[154].  
While NSCs provide the benefit of being able to 
give rise to neurons as well as glia, the use of GRPs 
harvested from fetal CNS has gained wide popularity 
in recent years for targeting astrocytes. Early studies 
documented extensive migration of transplanted GRPs 
in injured and intact spinal cord and differentiation 
into cells of the glial lineage, predominantly into 
astrocytes[112]. Transplantation of these cells into 
thoracic SCI reduced scar formation and expression 
of growth-inhibiting proteoglycans; however, no 
axon outgrowth was observed[155]. This obstacle was 
overcome by pre-differentiating GRPs into astrocytes 
(GDAs) by treatment with BMP-4. These GDAs were 
able to promote axon outgrowth when transplanted 
into lesioned spinal cord without causing neuropathic 
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pain[156]. These investigators also differentiated 
GRPs into astrocytes by treatment with a different 
estrogenic signaling molecule, CNTF. This type of 
GDA however failed to promote axon regeneration 
and promoted thermal hyperalgesia and mechanical 
allodynia following transplantation into lesioned spinal 
cord[115]. These studies highlighted that heterogeneous 
astrocyte populations may have distinct therapeutic 
potentials. Contrasting results from the Fischer lab 
indicated that, although heterogeneous, both BMP-4 
and CNTF GDAs promoted axon outgrowth to a similar 
extent[157]. Although it is not possible to compare in 
detail the precursor populations used by the two labs, 
the properties of specific glial precursor populations, 
differences in the culture conditions, and different 
transplantation and tracing protocols may have led to 
these contrasting results. Advantages derived from the 
graft are manifold. For example, a recent report from 
the Proschel lab illustrated an underlying mechanism 
through which BMP4-GDAs promote axon regeneration 
involving secretion of periostin[158]. 
While the above-mentioned studies involving 
rodent GRPs provided an understanding of their 
properties and therapeutic potential, further studies 
involving more clinically relevant human GRPs 
were designed based on these previous studies. 
hGRPs harvested from fetal human brain were pre-
differentiated into astrocytes (hGDAs) by treatment 
with BMP-4 and transplanted into injured spinal 
cords of athymic rats. Graft expansion was seen over 
an 8 wk time period, and in both hGRP and hGDA 
transplant groups, cyst and glial scar formation was 
reduced. Although there was no significant motor 
recovery, lack of neuropathic pain and permissive 
properties of these cells make them promising 
therapeutic candidates after SCI[159]. Based on their 
rodent GRP work, the Fischer group generated GDAs 
by treatment with either CNTF or BMP-4 and showed 
that these cells have similar therapeutic potential in 
terms of promotion of axon generation[160], whereas 
the Davies and Proschel groups again reported 
contrasting results[116]. These differences may be 
related to the age, region and technique of isolation of 
hGRPs, as well as differences in the culture conditions 
used by the two labs.
In recent years, the discovery of induced pluripotent 
stem cells (iPSC) cells has generated great excitement 
as large quantities of clinically relevant mature cell types 
can be generated from these pluripotent cells, without 
facing the ethical concerns presented by pluripotent 
embryonic stem cells (ESCs). However, this field is 
in its infancy, especially in the context of astrocytes. 
Recently, the Zhang laboratory developed a protocol 
for producing large quantities of regionally specific 
astrocytes from ES and iPSC cells[69]. A shortcoming of 
this study however is that it required 6 mo of culturing. 
Shorter duration protocols were subsequently reported, 
but these produced mainly populations of immature 
astrocytes[161,162]. Astrocyte maturation takes place in 
two distinct phases and marker expression for these 
phases has been characterized, which led to the 
development of protocols that generate astrocytes with 
mature phenotypes. While the treatment of immature 
astrocytes with FGF1 or FGF2 promoted up-regulation 
of maturation markers such as glutamate transporters 
and downregulation of GFAP, treatment with tumor 
necrosis factor- pushed cells toward a reactive astrocyte 
phenotype. These cells can be used to model human 
pathological processes in vitro and in vivo as well as for 
therapeutic transplantation[163]. More recently the Zhang 
laboratory reported another shorter duration protocol 
for generating astrocytes from iPSCs by differentiation 
of these cells into neuroepithelial cells, followed by 
removal of mitogen and treatment with CNTF to induce 
differentiation into astrocytes[70]. Recently, the Maragakis 
lab conducted transplantation of iPSC- and ESC-derived 
immature astrocytes into rodent spinal cord. Although 
limited, the grafts showed long-term survival, with 
less than 5% of the transplanted cells surviving at 12 
wk post-transplantation. Furthermore, graft derived 
astrocytes expressed markers of mature, quiescent 
astrocytes such as AQP4, EAAT1, EAAT2, as assessed 
by immunostaining analysis and gene expression 
profiling, suggesting that these cells are a promising 
resource for transplantation therapies[164]. Additional 
reports suggest that it is important to evaluate the in 
vivo safety of these cells, especially in terms of their 
tumor formation tendency, prior to their use for clinical 
transplantation[165,166]. Recent work from the Lepore 
lab, conducted as an extension of their work related to 
rodent GRPs, generated glial progenitors from human 
iPSCs, followed by further differentiation into astrocytes. 
Following transplantation into injured spinal cord, these 
cells showed long-term survival, no tumor formation, 
and efficient differentiation into GFAP expressing cells. 
These cells could even be engineered to express GLT1, 
suggesting that hiPSCs could be used as a safe source 
for transplantation therapies for targeted replacement of 
astrocytes in SCI and other CNS diseases (unpublished 
data).  
Until recently, the SCI field primarily focused on 
the role of astrocytes with regard to scar formation 
and their inhibitory effects on axon re-growth. Recent 
studies however have elucidated their heterogeneity 
and the changes exhibited by these cells following 
SCI, thereby underscoring the need to preserve their 
normal physiological functions. Studies mentioned 
above, as well as other studies that are not detailed 
here, are indicative of the growing appreciation of cell 
transplantation therapies for therapeutically targeting 
astrocytes in SCI. 
With a special focus on chronic SCI conditions, 
many clinical trials based on the transplantation of 
unmodified mesenchymal, neural or bone-marrow 
stem cells have been launched around the world[167-171]. 
Among phase 1 studies, most of them have focused 
on safety measurements and graft survival according 
to different routes of administration (mostly intrathecal 
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or focal intraparenchymal delivery). All of these studies 
have reported transplantation of stem cells as a risk-
free procedure. To our best knowledge, none of the 
current human trials are specifically addressing the 
replacement of lost astrocytes following SCI.
CONCLUDING REMARKS AND FUTURE 
DIRECTIONS 
We must admit that, despite numerous preclinical animal 
studies demonstrating improvement in a variety of 
functional outcomes following astrocyte transplantation, 
the variability and the poor reproducibility of the results 
still hinder full clinical translation. The variability might be 
partly explained by the limited survival of transplanted 
cells in diseased spinal cord tissue. In published preclinical 
ALS and SCI studies, cell graft survival was found to be 
usually between 5% and 32% of the initial dose and was 
often assessed at early time points post-transplantation. 
Inter-laboratory discrepancies might also be due to the 
source or type of astrocytes (or precursors) used in 
the transplantation paradigms. Indeed, astrocytes, in 
rodents and even more in humans, are a broad class of 
CNS cells endowed with specific functions according to 
their location, their morphology, their degree of maturity 
and their activation state. Finally, lack of standardization, 
different type of cells, different animal species and single 
targeting strategies of multifactorial diseases may also 
be part of the failures. Therefore, future protocols should 
aim at standardizing the culture conditions, verifying 
the astrocyte population homogeneity, the cell purity 
and, above all, at enhancing cell survival after in vivo 
transplantation. Researchers are also encouraged to 
provide preclinical data about long-term follow-up of 
engrafted cells, including survival time, differentiation 
pattern and CNS integration several months post-
transplantation.
During this last decade, detailed molecular dissection 
of astroglial populations has shown that astrocytes are 
active players in CNS homeostasis and far more than 
basic fibroblast-like cells of the CNS. Understanding 
the molecular mechanisms underlying the normal 
biology of astrocytes as well as their behavior during 
pathological conditions will provide us with undoubtedly 
novel astrocyte-specific therapeutic targets. Especially 
regarding ALS and SCI that share several common 
pathophysiology mechanisms, targeting astrocytes, 
whose dysfunction is now well established from animal and 
human studies, might be a promising therapeutic strategy. 
As far as we know, oxidative stress, neuroinflammation 
and glutamate excitotoxicity are all pathological events 
in which astrocytes are actively involved. Therapeutics 
that address each separately or all-in-one these specific 
pathological events are of great relevance to ALS and 
SCI.  
Stem cell based therapy for ALS and SCI includes 
three main aims: (1) replacement of lost nervous 
cells for restoring homeostatic functions of the CNS; 
(2) neuroprotection of unaffected surrounding tissue 
i.e., by secretion of neurotrophic factors or anti-
inflammatory molecules; and (3) enhancement of 
the endogenous repair process. Based on the biology 
and the known functions of astrocytes, here are a few 
examples of neuroprotection-based mechanisms that 
are under investigation and might deserve particular 
attention in future transplantation paradigms targeting 
astrocytes. 
Increased oxidative stress has been implicated 
in the pathogenesis of ALS and SCI, leading to the 
testing of different antioxidants in affected patients. 
Several studies have demonstrated that astrocyte-
secreted glutathione greatly contributes to neuro-
protection against oxidative stress. One of the main 
regulators of glutathione production and release is 
the transcription factor Nrf2. ALS mice with astrocyte 
driven Nrf2 overexpression showed increased lifespan, 
better functional outcomes and lower glial reactivity 
in spinal cord tissue[172]. Accordingly, it would be 
interesting to investigate the effect of transplantation 
of Nrf2-overexpressing astrocytes. Stat3 is another 
transcription factor regulating GSH synthesis[173], as 
well as a “master-switch” that mediates transition 
from quiescent to reactive astrocyte. Following SCI, 
transgenic mice ablated for Stat3 in the astroglial 
population showed less reactive astrocytes in the spinal 
cord, resulting in more widespread neuroinflammation, 
motor neuron loss and axonal damage and thus worsened 
motor deficits compared to wild-type counterparts. 
This study and others demonstrates that Stat3 is a key 
transcription factor controlling astrocyte reactivity during 
neurodegenerative processes, providing a potential target 
for intervention[174,175]. 
Far from being science fiction, researchers can 
genetically modify (stem) cells to make them produce 
more growth factors or proteins of interest, as Trojan 
horses to deliver molecules to specific CNS locations. 
For instance, NSCs engineered to overexpress CNTF 
exert neuroprotection by in situ differentiation into 
supportive astrocytes in a mouse model of photoreceptor 
degeneration[176]. Similarly, NSCs overexpressing nerve 
growth factor showed beneficial effects on cognitive 
functions after CNS transplantation and astrocyte 
differentiation in a learning deficit mouse model[177]. 
Another example is illustrated in a recent report from 
Gowing[178]. This group engineered GDNF-secreting 
human neural progenitors that were able to survive up 
to 7.5 mo after intraspinal transplantation, differentiate 
mainly into astrocytes and still maintain locally high levels 
of GDNF. More specifically, intranigral transplantation of 
astrocytes transduced with a lentiviral vector expressing 
GDNF resulted in sustained local production of growth 
factor and provided neuroprotection in a rat model of 
Parkinson[179]. Lastly, genetically-modified astrocytes 
designed to secrete BDNF promoted retinal ganglion cell 
survival[180], and transplantation of neurotrophin-releasing 
GRPs improved functional and histological outcomes after 
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SCI[181]. Growth factors released from transplanted cells 
act in a paracrine manner on surrounding host tissue but 
are likely to also act in an autocrine manner on grafted 
cells to promote survival and/or a specific differentiation 
pattern. All aforementioned examples should encourage 
us to investigate more deeply the therapeutic potential 
of grafted exogenous astrocytes or stem cell-derived 
astrocytes in neurodegenerative and traumatic CNS 
diseases, as well as to think about novel genetically-
modified cells that specifically target pathogenic events 
occurring during ALS or SCI. 
Inspired from encouraging results obtained following 
transplantation of GLT1-overexpressing GRPs in the 
rat model of ALS[104], the Lepore lab is studying their 
applicability and evaluating their efficacy in clinically-
relevant SCI models[182,183]. The rationale behind such an 
approach is based on the findings that, following SCI, 
astrocyte GLT1 expression and function are compromised, 
resulting in excitotoxicity-induced cell death during the 
delayed secondary injury phase[105]. Unpublished data 
from our group show that transplantation of astrocytes 
engineered to overexpress GLT1 can prevent excitotoxicity 
and protect respiratory phrenic motor neurons following 
cervical SCI. While unmodified transplants showed robust 
survival, they expressed relatively low levels of GLT1 
in injured spinal cord. Excitingly, GLT1 overexpressing 
transplant-derived astrocytes continued to express high 
levels of GLT1 protein following transplantation into 
the injured spinal cord and promoted survival of these 
important phrenic motor neurons and preservation of 
diaphragm function (unpublished work).  
Finally, although ALS and SCI share many similarities 
including the death of spinal motor neurons, it must be 
emphasized that important differences between two 
diseases exist. ALS is a progressive neurodegenerative 
condition starting with discrete and asymptomatic 
loss of motor neurons in remote specific regions of 
the CNS (upper and lower motor neurons), whose 
symptomatology becomes apparent at approximately 
50% of motor neuron loss and fatally progresses when 
disease affects bulbar and/or spinal respiratory centers. 
Therefore, therapeutic strategies in ALS, once diagnosed, 
should focus on astrocyte-mediated neuroprotection 
that prevent further motor neuron loss, worsening of 
functional outcomes and delayed fatal respiratory failure. 
Unlike ALS, SCI is characterized by different temporal 
sequence of events. First, acute and sub-acute phases 
following the initial trauma in the first hours-by-days 
post-injury result in a hostile environment in the spinal 
cord around the lesion epicenter, including inflammation, 
excitotoxicity and oxidative stress that lead to more 
cell loss and thus extension of initial lesion. This narrow 
time window would be appropriate for interventional 
strategies targeting astrocytes that favor neuroprotection 
or compensate for lost astrocyte-specific functions. 
At later time points, during the chronic stage of SCI, 
characterized by the resolution of subacute events, glial 
scarring and reorganization of spinal tissue architecture, 
one can imagine designing astrocyte transplants to make 
scar tissue permeable to axonal regrowth, to promote 
invasion by remyelinating oligodendroglial precursors, 
or to facilitate overall rewiring of ascending/descending 
tracts in the spinal cord.
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